TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04765865

Intervention type: OTHER
Intervention: SHAKE Package
Description: The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).

Intervention type: OTHER
Intervention: SHAKE Package
Description: The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).

Intervention type: OTHER
Intervention: SHAKE Package
Description: The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
Study: NCT06046443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB54640
Description: Oral daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB54640
Description: Oral daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB54640
Description: Oral daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB54640
Description: Oral daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to LB54640
Study: NCT04848974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study: NCT06304441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
Study: NCT05121922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Psychological treatment provided by the patient's regular general practitioner
Study: NCT06304441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
Study: NCT05921448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigripetra
Description: Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
Study: NCT04828538

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily 4000 IU Vitamin D for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily 4000 IU Vitamin D for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily 4000 IU Vitamin D for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily 4000 IU Vitamin D for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega DHA / EPA
Description: Daily 1000mg Omega DHA/EPA for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega DHA / EPA
Description: Daily 1000mg Omega DHA/EPA for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega DHA / EPA
Description: Daily 1000mg Omega DHA/EPA for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega DHA / EPA
Description: Daily 1000mg Omega DHA/EPA for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin B complex and Zinc Acetate
Description: Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin B complex and Zinc Acetate
Description: Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin B complex and Zinc Acetate
Description: Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin B complex and Zinc Acetate
Description: Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04934254

Intervention type: OTHER
Intervention: Attitude Scale
Description: 26-item related to scale will construct and apply to nurses for creating scale
Study: NCT05380596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepharmaceutical Care
Description: The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
Study: NCT06404346

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Velocity Thrust
Description: Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Bowen therapy
Description: participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
Study: NCT05640739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demonstration method for the use of the Metered Dose Inhaler
Description: The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video watching method for the use of the Metered Dose Inhaler
Description: The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
Study: NCT06223477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich Fibrin
Description: PRF will be injected distal to the canine on the experimental side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin Dꝫ will be injected distal to the canine on the experimental side
Study: NCT06218836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-inflated endotracheal tube
Description: The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-inflated endotracheal tube
Description: The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
Study: NCT06443385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDMP Legal Mandate E-mail
Description: E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDMP Clinical Benefit E-mail
Description: E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
Study: NCT05266001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: same as arm/group description

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as arm/group description
Study: NCT04295486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Non-enteric coated 81 mg Aspirin tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Non-enteric coated 81 mg Aspirin tablet.
Study: NCT05602766

Intervention type: DRUG
Intervention: NGENLA (Somatrogon)
Description: Dosage, Frequency: Refer to the latest package insert.
Study: NCT05752721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition to Online Ordering
Description: The intervention food pantry will transition to online ordering at least once.
Study: NCT05945680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
Study: NCT05680740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTAMA® (tapinarof) Cream 1%
Description: VTAMA® (tapinarof) Cream 1% applied topically once daily
Study: NCT06468384

Intervention type: PROCEDURE
Intervention: thoracic erector spinae plane (ESP) block
Description: The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
Study: NCT05852769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986196
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Specified dose on specified days
Study: NCT05886985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MatriPlax
Description: MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
Study: NCT04562753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maïa® TMC Prosthesis (Lépine Groupe)
Description: Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
Study: NCT05804292

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration

Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration
Study: NCT06309797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental brush+HA
Description: interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental brush
Description: interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
Study: NCT04562753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APL Suspensionplasty
Description: Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
Study: NCT05852769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Specified dose on specified days
Study: NCT06580925

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tape
Description: sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: kinesio tape
Description: Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic tape
Description: Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators
Study: NCT05259176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (sham-tDCS)
Description: The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Behavioural
Description: Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioural
Description: Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
Study: NCT05852769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days
Study: NCT04973189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
Study: NCT04969796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH Hope
Description: REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REACH Hope
Description: REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
Study: NCT04767308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT125A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, fludarabine
Description: Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
Study: NCT05921448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flumist
Description: Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
Study: NCT05483972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Prediabetes Diet Intervention
Description: Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
Study: NCT05170945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early bowel preparation for colonoscopy
Description: Early (\<24 hours) bowel cleansing prior to colonoscopy.
Study: NCT05852769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Specified dose on specified days
Study: NCT06408792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deepithelized graft and protection technique
Description: To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deepithelized graft and protection technique
Description: To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deepithelized graft and protection technique
Description: To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
Study: NCT05852769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Specified dose on specified days
Study: NCT06040463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Training (DSMT)
Description: The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education \& portion control; Session 3 - Tips \& Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Training (DSMT)
Description: The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education \& portion control; Session 3 - Tips \& Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.